Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease | Zendy

Satoru Hagiwara | Zendy; Naoshi Nishida | Zendy; Tomohiro Watanabe | Zendy; Toshiharu Sakurai | Zendy; Hiroshi Ida | Zendy; Yasunori Minami | Zendy; Masahiro Takita | Zendy; Tomohiro Minami | Zendy; Mina Iwanishi | Zendy; Hirokazu Chishina | Zendy; Kazuomi Ueshima | Zendy; Yoriaki Komeda | Zendy; Tadaaki Arizumi | Zendy; Masatoshi Kudo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Outcome of Combination Therapy with Sofosbuvir and Ledipasvir for Chronic Type C Liver Disease

Author(s) -

Satoru Hagiwara,

Naoshi Nishida,

Tomohiro Watanabe,

Toshiharu Sakurai,

Hiroshi Ida,

Yasunori Minami,

Masahiro Takita,

Tomohiro Minami,

Mina Iwanishi,

Hirokazu Chishina,

Kazuomi Ueshima,

Yoriaki Komeda,

Tadaaki Arizumi,

Masatoshi Kudo

Publication year - 2016

Publication title -

oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.987

H-Index - 98

eISSN - 1423-0232

pISSN - 0030-2414

DOI - 10.1159/000451010

Subject(s) - medicine , sofosbuvir , ledipasvir , cirrhosis , adverse effect , heart failure , atrial fibrillation , liver disease , gastroenterology , heart disease , bradycardia , chronic hepatitis , ribavirin , heart rate , immunology , blood pressure , virus

Recently, the treatment of chronic hepatitis C has markedly advanced. A phase III clinical study of combination therapy with sofosbuvir (SOF) and ledipasvir (LDV) was conducted in Japan, and the additive therapeutic effects were reported. In this study, we report the results of treatment in our hospital.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research